<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04279327</url>
  </required_header>
  <id_info>
    <org_study_id>immuno-cytology001</org_study_id>
    <nct_id>NCT04279327</nct_id>
  </id_info>
  <brief_title>Cell Block Immunohistochemistry in Effusion Cytology</brief_title>
  <official_title>Diagnostic Value of Cell Block Immunohistochemistry in Effusion Cytology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cytology is usually the first step in investigating serous effusions, to either detect or
      exclude an underlying malignancy. This study will try to answer the need for improved
      diagnostic yield of cytologic examination by cell block technique and immunohistochemical
      testing of three markers which are EZH2, Claudin-4 and MOC-31.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study that will be conducted at the pathology lab of Assiut University
      Hospital. The study will include effusion specimens (pleural, peritoneal &amp; pericardial) and
      the aspirated fluid will be examined for physical characters e.g. color and appearance.

      The sample will be divided into 2 equal parts: one for conventional smear preparation, and
      the other for cell block. A minimum of 2 thin smears will be prepared and stained with
      Papanicolou stain.

      Cell block sections of 4-6 Î¼ thickness will be prepared and stained with the hematoxylin and
      eosin stain (H&amp;E).

      For immunohistochemistry, cell blocks will be used. Expression of claudin 4, EZH2, and MOC-31
      will be evaluated in benign and malignant cells by using immunoperoxidase technique.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic performance of EZH2</measure>
    <time_frame>within 48 hours</time_frame>
    <description>sensitivity and specificity of EZH2 for diagnosis of malignancy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic performance of claudin4</measure>
    <time_frame>within 48 hours</time_frame>
    <description>sensitivity and specificity of claudin-4 for diagnosis of malignancy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic performance of MOC-31</measure>
    <time_frame>within 48 hours</time_frame>
    <description>sensitivity and specificity of MOC-31 for diagnosis of malignancy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of malignancy among cases presenting with effusion</measure>
    <time_frame>one year</time_frame>
    <description>percentage of cases diagnosed with malignancy among all cases presenting with effusion</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Effusion Pleural</condition>
  <condition>Ascites</condition>
  <condition>Pericardial Effusion</condition>
  <arm_group>
    <arm_group_label>cases</arm_group_label>
    <description>cytology positive for malignancy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controls</arm_group_label>
    <description>cytology negative for malignancy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        all cases that have serous effusion of undiagnosed underlying aetiology.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all cases with serous effusion of unknown aetiology including ascites, pleural or
             pericardial effusions.

        Exclusion Criteria:

          -  No exclusion criteria from the histopathologist perspective, i.e. all cases that
             undergone diagnostic aspiration are eligible for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aliaa EM Mahmoud, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assiut University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aliaa EM Mahmoud, MSc</last_name>
    <phone>+201007508736</phone>
    <email>aliaa.elhosainy88@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assiut University Hospital</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Sundling KE, Cibas ES. Ancillary studies in pleural, pericardial, and peritoneal effusion cytology. Cancer Cytopathol. 2018 Aug;126 Suppl 8:590-598. doi: 10.1002/cncy.22021. Review.</citation>
    <PMID>30156768</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>February 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Aliaa Elhosainy Mohammad Mahmoud</investigator_full_name>
    <investigator_title>Associate Lecturer</investigator_title>
  </responsible_party>
  <keyword>immunohistochemistry</keyword>
  <keyword>cytology</keyword>
  <keyword>moc 31 monoclonal antibody, human</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pericardial Effusion</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

